RET in Lung Cancer: The Next Big Target?

GRACE Videos and Articles

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

 

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Comments

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation